- Noadjuvant chemotherapy and pathological complete remission in patients under 35 yearsPublication without faculty affiliation
- Neoadjuvant treatment of early breast cancer2019 | Publication without faculty affiliation
- Nab-paclitaxel in neoadjuvant treatment of breast cancer2018 | First Faculty of Medicine
- Use of Trastuzumab for Neoadjuvant Therapy of HER2+ Breast Cancer - 5-Years of Experience in a Single Clinic2018 | First Faculty of Medicine
- Adjuvantní a neoadjuvantní léčba časného HER pozitivního karcinomu prsu. Specifika léčby HER2 pozitivního / HR pozitivního karcinomu prsu2022 | Publication without faculty affiliation
- Current indications for systemic neoadjuvant treatment in breast cancer patients2015 | Publication without faculty affiliation
- Personalization of neo/adjuvant treatment of HER2-positive breast cancer is the key to achieve the best results2022 | First Faculty of Medicine
- Neoadjuvant treatment of HER2-positive breast cance2023 | First Faculty of Medicine
- Immunotherapy in the treatment of triple negative breast cancer2022 | First Faculty of Medicine
- Adjuvant breast radiotherapy after neoadjuvant systemic therapy2022 | Third Faculty of Medicine
- Combination of neoadjuvant chemoradiotherapy and epidermal growth factor receptor inhibitors in the treatment of rectal adenocarcinoma2014 | First Faculty of Medicine
- Eskalace a deeskalace léčby pacientek s karcinomem prsu v roce 20212022 | First Faculty of Medicine
- Revelation in the treatment of triple-negative breast cancers2020 | First Faculty of Medicine
- Predictive markers in breast cancer2021 | First Faculty of Medicine
- Treatment of HER2-positive breast cancer in 20202020 | First Faculty of Medicine